/
AORT
$22.39-$1.22 (-5.17%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.1B
49M shares
52-week range
$19.16 – $48.25
11% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
Price (6 mo)
Loading chart…
Change+$3.67
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $262.8M | $276.2M | $253.2M | $298.8M | $313.8M | $354.0M | $388.5M | $441.3M |
| Cost of revenue | $89.9M | $93.2M | $85.4M | $101.3M | $111.3M | $124.8M | $139.8M | $170.9M |
| Gross profit | $173.0M | $183.0M | $167.8M | $197.5M | $202.5M | $229.2M | $248.8M | $270.5M |
| Gross margin | 65.8% | 66.3% | 66.3% | 66.1% | 64.5% | 64.7% | 64.0% | 61.3% |
| R&D | $23.1M | $23.0M | $24.2M | $35.5M | $38.9M | $28.7M | $28.5M | $31.0M |
| Operating income | $9.3M | $17.0M | $2.4M | $8.1M | $6.2M | $5.7M | $38.9M | $26.7M |
| EBITDA | $30.2M | $34.8M | $20.2M | $26.0M | $25.7M | $26.8M | $51.0M | $63.8M |
| Net income | −$3.8M | $1.7M | −$16.7M | −$14.8M | −$19.2M | −$30.7M | −$13.4M | $9.8M |
| Net margin | -1.4% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% |
| EPS (diluted) | -0.10 | 0.05 | -0.44 | -0.38 | -0.48 | -0.75 | -0.32 | 0.21 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $486M | $0.10 | $0.09–$0.10 | 5 |
| 2027 | $540M | $0.41 | $0.40–$0.42 | 5 |
| 2028 | $601M | $0.80 | $0.70–$0.97 | 4 |
| 2029 | $678M | $1.19 | $1.17–$1.21 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Artivion, Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
www.artivion.com- Employees
- 1,800
- IPO / List date
- Feb 11, 1993
- HQ
- KENNESAW, GA
Held by traders on TradeandTell
No one on the platform currently holds AORT.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AORT as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded AORT yet.
